Key result
Restorer bare-metal iliac stent undergoes prospective 12-month clinical evaluation in 200 patients.
Why the study?
Evidence regarding optimal stent selection in endovascular treatment of aorto-iliac lesions remains inconclusive, particularly in complex TASC C and D disease. Both bare metal stents and covered stents are widely used, yet comparative evidence is limited by study heterogeneity and selection bias.
What is the long-term safety and efficacy (freedom from target lesion revascularization, major amputation, and restenosis within 12 months) of the Restorer bare metal stent system in patients with symptomatic aorto-iliac lesions?
Observational (n=200)
Open-label
Yes
What is the long-term safety and efficacy (freedom from target lesion revascularization, major amputation, and restenosis within 12 months) of the Restorer bare metal stent system in patients with symptomatic aorto-iliac lesions?
This study protocol outlines the prospective, multicenter BARISTA trial designed to evaluate the 24-month safety and efficacy of the Restorer bare metal stent in 200 patients with TASC A-D aorto-iliac lesions to facilitate comparison with contemporary covered stent data.
Answers are grounded in this paper and cite their sources.
Prospective bare metal iliac stent cohort underway; leaves open whether outcomes match covered stents in complex lesions.
Background Evidence regarding optimal stent selection in endovascular treatment of aorto-iliac lesions remains inconclusive, particularly in complex TASC C and D disease. Interpretation of existing data is complicated by study heterogeneity and selection bias. Both bare metal stents (BMS) and covered stents (CS) are widely used, yet comparative evidence remains limited. The BARISTA trial aims to prospectively evaluate the safety and efficacy of the Restorer iliac stent system (iVascular) and to compare its outcomes with those reported in contemporary studies assessing covered stents. Methods Between July 2022 and June 2024, this prospective multicenter study enrolled 200 patients across 14 Belgian centers. The objective is to assess two-year safety and efficacy outcomes of the Restorer iliac stent system in symptomatic aorto-iliac disease. The primary composite endpoint includes: (1) freedom from target lesion revascularization (TLR), (2) freedom from major amputation, and (3) absence of restenosis within 12 months. TLR is defined as any repeat intervention within the treated segment, including 5 mm proximal and distal to the lesion. Restenosis is defined as > 50% stenosis on duplex ultrasound with a systolic velocity ratio > 2.4. Discussion By analyzing outcomes in a large prospective cohort and comparing results with contemporary CS data, the BARISTA trial aims to support evidence-based stent selection in aorto-iliac disease. Trial registration ClinicalTrials.gov ID: NCT05293002 (2022-03-23)
No takes yet. Share an insight, caveat, or question.
Maene et al. (2026) conducted an observational in Symptomatic aorto-iliac occlusive disease (TASC A-D lesions) (n=200). Restorer balloon-expandable bare metal iliac stent system vs. Single-arm (historical comparison planned with iCover covered stent from the iliCo trial) was evaluated on Composite of freedom from target lesion revascularization (TLR), freedom from major amputation, and absence of restenosis (>50% stenosis on duplex ultrasound with systolic velocity ratio >2.4) within 12 months. The Restorer bare metal iliac stent system is being prospectively evaluated in 200 patients across 14 Belgian centers for 12-month freedom from TLR, major amputation, and restenosis.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: